A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
10actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study terminated as part of strategic considerations and not based on safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-06 | actual | When the study began enrolling |
| Primary completion | 2025-10-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-03 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neoplasms
- Non-small-cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Ovarian Carcinoma
Interventions
- Drug: PF-07826390 — also filed as LILRB1/2
- Biological: sasanlimab — also filed as PF-06801591
- Other: SOC (anti-PD-1 + platinum -based chemo)
Primary outcomes
what the primary-completion date above is the date OFPART 1: Number of participants with Dose-limiting toxicities (DLT)
measured First cycle, Day 1 up to Day 28
PART 1 & 2: Incidence of Adverse Events (AE)s
measured From start of the treatment and up to 90 days after last dose or start of new anticancer therapy, whichever occurred first.
PART 1 & 2: Number of participants with laboratory abnormalities
measured From start of the treatment and up to 90 days after last dose or start of new anticancer therapy, whichever occurred first.
Part 2: Objective Response - Number of Participants With Objective Response
measured Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed